HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses.

ABSTRACT: We used a proteomic approach for identifying molecules involved in the pathogenesis of chronic lymphocytic leukemia (CLL). We investigated 14 patients who were completely concordant for IgV(H) mutational status (unmutated vs. mutated), CD38 expression (positive vs. negative), and clinical behavior (progressive vs. stable); these patients were characterized as having either poor or good prognoses. The 2 patient subsets differed in the expression of hematopoietic lineage cell-specific protein 1 (HS1). In patients with poor prognoses, most HS1 protein was constitutively phosphorylated, whereas only a fraction was phosphorylated in patients with good prognoses. This difference was investigated in a larger cohort of 26 unselected patients. The survival curve of all 40 patients analyzed revealed

SUBMITTER: Scielzo C 

PROVIDER: S-EPMC1136999 | biostudies-literature | 2005 Jun

REPOSITORIES: biostudies-literature